Abstracts tagged "Inflammation"

Abstract Number: 2432 • ACR Convergence 2023
Wnt Signaling Drives Pathogenic Stromal Inflammation in Inflammatory Arthritis
Alisa Mueller¹, Angela Zou², Lucy-Jayne Marsh³, Samuel Kemble⁴, Saba Nayar³, Emily Taylor³, Triin Major³, David Gardner⁵, Gerald F.M. Watts¹, Cassandra Murphy¹, Roche Fibroblast Network Consortium⁶, Adam Croft³, Andrew Filer³, Christopher Buckley⁷, Kevin Wei⁸, ilya Korsunsky¹, Soumya Raychaudhuri¹ and Michael Brenner⁸, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³University of Birmingham, Birmingham, United Kingdom, ⁴University Birmingham, Rugeley, United Kingdom, ⁵University of Birmingham, Havelock North, New Zealand, ⁶Roche, Basel, Switzerland, ⁷University of Oxford, Oxford, United Kingdom, ⁸Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Synovial fibroblasts are a promising therapeutic target in rheumatoid arthritis (RA) where they can adopt inflammatory or destructive phenotypes and directly promote bone and…
Abstract Number: 0055 • ACR Convergence 2023
Elevated LINE-1 Expression in SLE Keratinocytes Leads to LINE-1 Reverse Transcriptase-dependent Type I Interferon Responses
Wenyan Miao¹, Daniel Rios¹, Mehrnaz Gharaee-Kermani², Craig Dobry², Artur Jaroszewicz¹, Cedric Arisdakessian¹, Enrique Garcia-Rivera¹, Nafeeza Hafeez¹, Brian Desrosiers¹, Jess Floro¹, Jared Steranka¹, Menachem Fromer¹, Dennis Zaller¹ and J. Michelle Kahlenberg², ¹Rome Therapeutics, Boston, MA, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Long Interspersed Element-1 (LINE-1) are retrotransposable DNA elements that make up ~17% of the human genome, and their role in health and disease is…
Abstract Number: 0399 • ACR Convergence 2023
Differential Synovial Tissue Enrichment of Oxylipins and Their Mediators Across Rheumatoid Arthritis Trajectory
Simone Perniola¹, Jessica Murillo-Saich², Barbara Tolusso³, Clara Di Mario³, Marco Gessi⁴, Dario Bruno⁵, Luca Petricca⁶, Maria Rita Gigante⁶, Elisa Gremese⁵, Monica Guma⁷ and Stefano Alivernini⁸, ¹Division of Clinical Immunology – Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ²Department of Medicine, University of California San Diego, La Jolla, CA, ³Immunology Research Core Facility – Gemelli Science and Technology Park (GSTeP) - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁴Division of Pathology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁵Division of Rheumatology, Institute of Rheumatology and Affine Sciences, School of Medicine, Catholic University of the Sacred Heart, Roma, Italy, ⁶Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁷University of California San Diego, La Jolla, CA, ⁸Immunology Research Core Facility, Gemelli Science and Technology Park, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy
Background/Purpose: Synovial membrane represents the target tissue of Rheumatoid Arthritis (RA) inflammation. Our study aimed to perform a comprehensive quantification of oxylipins and their precursors…
Abstract Number: 0864 • ACR Convergence 2023
Proteomic Analysis of Circulating Neutrophils from Osteoarthritis Patients Shows Metabolic Dysregulation That Is Associated with Decreased Physiologic Apoptosis
Jennifer Amsler¹, Morgane Le Gall², Camille Daste³, François Rannou³ and Véronique Witko-Sarsat², ¹Institut Cochin, Bern, Switzerland, ²Institut Cochin, Paris, France, ³Hôpital Cochin, Paris, France
Background/Purpose: Osteoarthritis (OA) has long been thought to be only of local mechanical origin. However, it has been shown recently that there is a phenotype…
Abstract Number: 1068 • ACR Convergence 2023
Multidisciplinary Prospective Study of Patients Treated with Immune Checkpoint Inhibitors Who Developed Rheumatic Immune-related Adverse Events
Mª Carmen López-González¹, Natividad Martínez Banaclocha², Montserrat García Araque², Yoel Montoyo Pujol² and Mariano Andrés³, ¹General University Hospital Dr. Balmis, Alacante, Spain, ²General University Hospital Dr. Balmis, Alicante, Spain, ³Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain
Background/Purpose: Immune checkpoint inhibitors (ICIs), by activating the immune system (specifically, T-cells), foster the reaction against tumor cells. However, parallelly, autoimmune phenomena, known as immune-…
Abstract Number: 1585 • ACR Convergence 2023
Defining Neutrophil-Mediated Renal Damage Triggered by Ultraviolet (UV) Skin Exposure
Angelique Cortez¹, Lindsay Mendyka², Fred Kolling³, Michael Whitfield¹ and Sladjana Skopelja-Gardner⁴, ¹Dartmouth College, Hanover, NH, ²Dartmouth Hitchcock, Lebanon, NH, ³Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Dartmouth-Hitchcock, Lebanon, NH
Background/Purpose: Lupus (SLE) is one of the leading causes of death in young women in the United States. Roughly ~80% of SLE patients experience sensitivity…
Abstract Number: 1745 • ACR Convergence 2023
Chronic Inflammation and Collagen IV Fragment Canstatin Influence Rheumatoid Arthritis Synovial Fibroblast and Endothelial Cell Interactions in Vitro and in Vivo
Corinna Heck¹, Sophie Haun¹, Daria Kürsammer¹, Klaus Frommer¹, Mona Arnold¹, Markus Rickert², Katrin Susanne Lips³, Stefan Rehart⁴, Ulf Müller-Ladner¹ and Elena Neumann¹, ¹Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, ²Dept. of Orthopaedics and Orthopaedic Surgery, University Hospital Giessen and Marburg, Giessen, Germany, ³Justus Liebig University Gießen, Department of Experimental Trauma Surgery, Giessen, Germany, ⁴Dept. of Orthopaedics and Trauma Surgery, Agaplesion Markus Hospital Frankfurt, Frankfurt, Germany
Background/Purpose: In the inflamed synovium of RA patients, increased and altered angiogenesis is a pathological feature. Key players are chronically activated RA synovial fibroblasts (RASF),…
Abstract Number: 1869 • ACR Convergence 2023
FDG-PET/CT for Diagnosing Polymyalgia Rheumatica Before, During and After a Short-term Prednisolone Cessation – a Prospective Study of 101 Patients
Andreas Wiggers Nielsen¹, Ib Tønder Hansen², Berit Dalsgaard Nielsen³, Søren Geill Kjær⁴, Jesper Blegvad-Nissen⁴, Christian Møller Sørensen³, Ellen-Margrethe Hauge¹, Lars Christian Gormsen² and Kresten Krarup Keller¹, ¹Aarhus University Hospital, Aarhus, Denmark, ²Aarhus University Hospital, Aarhus N, Denmark, ³Department of Internal Medicine, Horsens, Denmark, ⁴Diagnostic Centre, Silkeborg, Denmark
Background/Purpose: Polymyalgia rheumatica (PMR) can be challenging to diagnose since other diseases may present with similar symptoms. As a result, a significant number of patients…
Abstract Number: 2437 • ACR Convergence 2023
Translocation of Intestinal Bacteria to Axial and Peripheral Joints in a Model of Spondyloarthropathy
Benjamin Cai¹, Rabina Giri², Helen Benham³, Linda Rehaume¹, Geoffery Strutton³, Anne-Sophie Bergot¹ and Ranjeny Thomas⁴, ¹Frazer Institute, The University of Queensland, Woolloongabba, Australia, ²Mater Research Institute-UQ, Woolloongabba, Australia, ³Princess Alexandra Hospital, Woolloongabba, Australia, ⁴Frazer Institute, The University of Queensland, Brisbane, Australia
Background/Purpose: In spondylarthropathy (SpA), such as psoriatic arthritis (PsA) and ankylosing spondylitis (AS), arthritis is often associated with gut inflammation. After systemic β-1,3-glucan (curdlan) injection,…
Abstract Number: 0057 • ACR Convergence 2023
GM-CSF receptor/SYK/JNK/FOXO1/CD11c Signaling Enhances Cell Migration to Promote Atherosclerosis
Daisuke Tsukui¹, Kimura Yoshitaka¹ and Hajime Kono², ¹Teikyo University School of Medicine, Itabashi-ku, Japan, ²Teikyo University School of Medicine, Tokyo, Japan
Background/Purpose: Atherosclerosis involves both dyslipidemia and chronic inflammatory disease; however, lipid-lowering agents do not completely eliminate the risks of cardiovascular events. In addition, chronic systemic…
Abstract Number: 0417 • ACR Convergence 2023
The Role of Rheumatoid Arthritis Flare in the Risk of Alzheimer’s Disease and Related Dementias: A Population-based Cohort Study
Chanakya Kodishala¹, Tina Gunderson², Edward Lovering², Rakesh Kumar², Cynthia Crowson², John Davis² and Elena Myasoedova², ¹Mayo Clinic Rochester Minnesota, Rochester, MN, ²Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) have increased risk for Alzheimer's disease and related dementias (AD/ADRD). Recent studies have reported an association between RA disease…
Abstract Number: 0866 • ACR Convergence 2023
A Novel 3D-Synovium-Immune Microenvironment Mimics Macrophage-Synovial Fibroblast Interactions in Inflammatory Arthropathies
André Tiaden¹, Simone Häner Massimi¹, Ulrich Walker², Diego Kyburz³ and Stavros Giaglis¹, ¹Laboratory for Experimental Rheumatology, Department of Biomedicine, University of Basel, Basel, Switzerland, ²Basel University Hospital, Basel, Switzerland, ³University Hospital Basel, Basel, Switzerland
Background/Purpose: Autoimmunity, trauma, or infection lead to devastating arthropathies, within enormous socioeconomic impact due to its high frequency and chronicity. The development of novel treatments…
Abstract Number: 1070 • ACR Convergence 2023
Safety of DMARDs in Rheumatologic Immune-related Adverse Events Associated with Immune Checkpoint Inhibitors: Data from a Monocentric Cohort in Hospices Civils De Lyon
Julien Seiller¹, Emmanuel Massy², Julien Peron³ and Cyrille Confavreux², ¹Centre Expert des Métastases Osseuses (CEMOS) - Service de Rhumatologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université de Lyon, Lyon, France, ²Centre Expert des Métastases Osseuses (CEMOS) - Service de Rhumatologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université de Lyon, INSERM UMR 1033-LYOS, Lyon, France, ³Service d’oncologie médicale. Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Université de Lyon, INSERM U1290, Lyon, France
Background/Purpose: Since Immune Checkpoint Inhibitors (ICI) revolution, oncologists face immune-related adverse events (irAEs) including rheumatologic irAEs with inflammatory arthritis. Treatment of rheumatologic irAE can be…
Abstract Number: 1603 • ACR Convergence 2023
Infection-Associated Antiphospholipid Antibodies and Their Potential Role in Sepsis Outcomes
Katarina Kmetova, Emily Chong, NaveenKumar K. Somanathapura, Sherwin Navaz, Lyndsay Kluge, Srilakshmi Yalavarthi, Jason Knight, Michael Maile and Yu Zuo, University of Michigan, Ann Arbor, MI
Background/Purpose: Antiphospholipid syndrome (APS) is an acquired autoimmune thrombophilia characterized by circulating antiphospholipid antibodies (aPL). While the association between aPL and infection has long been…
Abstract Number: 1749 • ACR Convergence 2023
Fatty Acid Synthase Is a Critical Repressor of Ferroptosis in Rheumatoid Arthritis
Qi Cheng, Mo chen, Xin chen, Yifan Xie, Yan Du and Huaxiang wu, The Second Affiliated Hospital Of Zhejiang University School Of Medicine, Hangzhou, China
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease with synovial inflammation as the main pathological feature, and can eventually lead to irreversible joint or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].